HEPAVEC AG

HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell engineering of hepatocytes (liver cells). HepaVec has developed new gene transfer systems (vectors), derivatives of baculovirus and an ovine (sheep) adenovirus (OAV), which enable efficient and specific delivery of therapeutic genes into human liver cells. In the combat against liver cancer, HepaVec's lead product regulates the cell cycle to selectively drive cancer cells to programmed cell death (apoptosis) and is scheduled to enter a Phase I/II clinical trial in 2000.

#SimilarOrganizations #Financial #More

HEPAVEC AG

Industry:
Biotechnology Medical Therapeutics

Address:
Berlin, Berlin, Germany

Country:
Germany

Status:
Active

Contact:
+49 30 94892282

Total Funding:
5.9 M USD


Similar Organizations

bird-c-logo

BIRD-C

BIRD-C is a privately held R&D biotechnology company based in Vienna, Austria.

not_available_image

Genopoietic

Genopoietic is a privately held biotechnology company.

kherion-technology-logo

Kherion Technology

Kherion Technology is a privately held biotechnology company.

somagenics-logo

SomaGenics

SomaGenics is a privately held biotechnology company.

stage-cell-therapeutics-logo

Stage Cell Therapeutics

Stage is a privately held biotech company active since 2005.

Acquisitions List

Date Company Article Price
1999-11-08 MondoGen MondoGen acquired by HepaVec AG N/A

Investors List

dka-capital_image

DKA Capital

DKA Capital investment in Series A - HepaVec AG

tvm-techno-venture-management_image

Techno Venture Management

Techno Venture Management investment in Series A - HepaVec AG

german-federal-ministry-of-education-and-research-bmbf_image

German Federal Ministry of Education and Research (BMBF)

German Federal Ministry of Education and Research (BMBF) investment in Grant - HepaVec AG

More informations about "HepaVec AG"

HepaVec AG - Crunchbase Company Profile & Funding

HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell …See details»

HepaVec AG - Funding, Financials, Valuation & Investors

Nov 8, 1999 Series A - HepaVec AG — German Federal Ministry of Education and Research . Yes: Grant - HepaVec AG — Acquisitions. Edit Acquisitions Section. Number of Acquisitions 1. …See details»

Hepavec - Products, Competitors, Financials, Employees, …

Developer of gene and cell-based therapeutic products for the treatment of currently incurable, malignant, inborn and acquired diseases of the liver. Use the CB Insights Platform to explore …See details»

General

Explore HepaVec AG profile on Finallot for insights on its team, products, and industry - HepaVec AG is a biotech company developing innovative therapies for liver diseases. with 5.9M in …See details»

TQ Therapeutics GmbH

Christin´s expertise lies in the field of commercial strategy and organization design with over 8 years of experience in strategy consulting for the pharmaceutical & life science industry, as …See details»

DeveloGen, HepaVec Combine In First German Biotech Merger

May 17, 2000 HepaVec was founded in 1996 as a company focusing on gene therapy strategies to fight liver diseases, while DeveloGen was created in 1998 by several well-known German …See details»

HepaVec AG - insights.citeline.com

HepaVec AG. 01 Nov 1998. With technology licensed from the Max Planck Society, HepaVec is developing liver-specific viral vector systems for human gene therapy. Also liver tissue …See details»

MondoGen - Crunchbase Company Profile & Funding

MondoGen was acquired by HepaVec AG on Nov 8, 1999. Transaction Name . MondoGen acquired by HepaVec AG . Acquired by . HepaVec AG . Announced Date Nov 8, 1999; …See details»

HepaVec AG - Drug pipelines, Patents, Clinical trials - Synapse

Explore HepaVec AG with its drug pipeline, therapeutic area, technology platform, 3 literature.See details»

HepaVec completes private financing - Pharmaceutical industry …

May 7, 2000 HepaVec AG, a Berlin, Germany-based biotechnology company specializingin the treatment of a broad range of liver diseases, has closed an 8 million Deutschemark ($3.7 …See details»

Germany's HepaVec & DeveloGen to merge - Pharmaceutical …

May 15, 2000 German biotechnology companies HepaVec and DeveloGen have announcedplans to merge, creating what they call "a leader in lifestyle disease therapeutics …See details»

Hepavec Stock Price, Funding, Valuation, Revenue & Financial …

See Hepavec funding rounds, investors, investments, exits and more. Evaluate their financials based on Hepavec's post-money valuation and revenue. Hepavec Stock Price, Funding, …See details»

Reactivation of the Previously Silenced Cytomegalovirus Major …

Department of Molecular Cell Biology, Humboldt-Universität, 1 and HepaVec AG at the Max-Delbrück-Center for Molecular Medicine, 2 Berlin, Germany. Find articles by Peter Löser. 1, …See details»

HepaVec AG - Crunchbase

HepaVec AG is a privately held biotechnology company. Start Free Trial . Chrome ExtensionSee details»

CONELIS Expert – Moritz Hillgenberg

Before that, he held positions as Scientific Director of Custos Biotechnologie GmbH and as project leader in the gene therapy program at HepaVec AG and Develogen AG. He started is career …See details»

HEPAVEC AG FUER GENTHERAPIE innovation strategy - GoodIP

HEPAVEC AG FUER GENTHERAPIE has a total of 17 patent applications. Its first patent ever was published in 1997. It filed its patents most often in Germany, WIPO (World Intellectual …See details»

HepaVec acquires majority stake in MondoGen - Pharmaceutical …

Nov 18, 1999 HepaVec acquires majority stake in MondoGen. hepavec, acquires, majority, stake, mondogen, germany, ag. Wednesday 2 October 2024. About. Contact. Login. VC & …See details»

HepaVec AG acquires MondoGen - 1999-11-08 - Crunchbase

Nov 8, 1999 MondoGen acquired by HepaVec AG . Save . Summary. Overview. Edit Overview Section. Acquired Organization: MondoGen MondoGen is a biotechnology company that …See details»

New Novartis Phase III data demonstrate meaningful efficacy and …

5 days ago These data will be presented during the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference held in Dallas, Texas, from March 16–19, 2025. The results …See details»

What is the difference between heptovac p plus and ovivac p plus

Oct 21, 2017 Heptavac P covers a few more diseases than Ovivac, lamb dysentry and black disease being 2 of them. Ovivac is normally cheaper but doesn't come in a small 50ml bottle …See details»

linkstock.net © 2022. All rights reserved